Table 1.
Participant Characteristics
| Healthy Control | COPD Group | ||||
|---|---|---|---|---|---|
| Baseline | 24 Weeks | 52 Weeks | P value | ||
| N | 29 | 82 | 82 | 82 | |
| Age | 60±9.83 | 66±10.59 | 66±10.59 | 67±10.59 | 0.659 |
| Male/Female | 26/3 | 76/6 | 76/6 | 76/6 | 0.988 |
| BMI | 24.91±3.10 | 26.33±5.29 | 23.32±4.77 | 22.34±3.61 | 0.669 |
| IBW% | 100.7±16.38 | 108.9±19.28 | 99.78±17.44 | 96.33±15.81 | 0.001 |
| WBC (10^9) | 6.24±5.57 | 6.08±4.31 | 7.49±3.59 | 7.82±6.85 | 0.038 |
| NEUT (10^9) | 5.13±1.22 | 5.29±3.16 | 5.85±2.94 | 5.41±3.15 | 0.11 |
| TLC (10^9) | 1.37±1.61 | 1.35±0.60 | 1.27±0.67 | 1.36±0.73 | 0.644 |
| Eos (10^9) | 0.19±0.31 | 0.14±0.12 | 0.16±0.27 | 0.12±0.16 | 0.121 |
| CRP (μg/L) | 0.12±1.61 | 0.39±0.14 | 0.26±0.31 | 0.42±0.17 | 0.492 |
| PCT (ng/mL) | 0.20±1.46 | 0.21±0.75 | 0.31±1.10 | 0.27±1.07 | 0.342 |
| CEA (ng/mL) | 4.43±4.78 | 3.80±2.90 | 4.75±6.36 | 3.20±2.26 | 0.285 |
| Glu (mmol/L) | 6.12±5.56 | 6.15±2.29 | 6.35±3.26 | 6.21±1.82 | 0.561 |
| TCH (mmol/L) | 3.71±5.54 | 3.92±1.19 | 4.27±1.01 | 3.97±0.89 | 0.077 |
| FEV1 (% predict) | 91.68±4.50 | 58.10±12.86 | 34.10±9.07 | 23.85±7.84 | 0.001 |
| FVC (% predict) | 90.33±4.63 | 69.45±15.89 | 71.15±14.11 | 72.00±16.96 | 0.832 |
| FEV1/FVC% | 82.52±8.71 | 56.01±6.97 | 43.22±4.12 | 36.19±5.89 | 0.001 |
Abbreviations: COPD, chronic obstructive pulmonary disease; BMI, body mass index; IBW, ideal body weight; WBC, white blood cell count; TLC, total lymphocyte count; NEUT, neutrophile granulocyte; EOS, eosinophilic granulocyte; CRP, C-reactive protein; PCT, procalcitonin; CEA, carcinoembryonic antigen; GLU, glucose; TCH, total cholesterol; FEV1, forced expiratory volume in 1second; FVC, forced vital capacity.